Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase II study evaluating the role of bortezomib in the management of relapsed acute promyelocytic leukemia treated upfront with arsenic trioxide.
Kulkarni U, Ganesan S, Alex AA, Palani H, David S, Balasundaram N, Venkatraman A, Thenmozhi M, Jeyaseelan L, Korula A, Devasia A, Abraham A, Janet NB, Balasubramanian P, George B, Mathews V. Kulkarni U, et al. Among authors: palani h. Cancer Med. 2020 Apr;9(8):2603-2610. doi: 10.1002/cam4.2883. Epub 2020 Feb 14. Cancer Med. 2020. PMID: 32059085 Free PMC article. Clinical Trial.
Rationale and efficacy of proteasome inhibitor combined with arsenic trioxide in the treatment of acute promyelocytic leukemia.
Ganesan S, Alex AA, Chendamarai E, Balasundaram N, Palani HK, David S, Kulkarni U, Aiyaz M, Mugasimangalam R, Korula A, Abraham A, Srivastava A, Padua RA, Chomienne C, George B, Balasubramanian P, Mathews V. Ganesan S, et al. Among authors: palani hk. Leukemia. 2016 Nov;30(11):2169-2178. doi: 10.1038/leu.2016.227. Epub 2016 Aug 18. Leukemia. 2016. PMID: 27560113 Free PMC article.
Arsenic Trioxide Enhances the NK Cell Cytotoxicity Against Acute Promyelocytic Leukemia While Simultaneously Inhibiting Its Bio-Genesis.
Alex AA, Ganesan S, Palani HK, Balasundaram N, David S, Lakshmi KM, Kulkarni UP, Nisham PN, Korula A, Devasia AJ, Janet NB, Abraham A, Srivastava A, George B, Padua RA, Chomienne C, Balasubramanian P, Mathews V. Alex AA, et al. Front Immunol. 2018 Jun 14;9:1357. doi: 10.3389/fimmu.2018.01357. eCollection 2018. Front Immunol. 2018. PMID: 29963052 Free PMC article.
Management of relapse in acute promyelocytic leukaemia treated with up-front arsenic trioxide-based regimens.
Fouzia NA, Sharma V, Ganesan S, Palani HK, Balasundaram N, David S, Kulkarni UP, Korula A, Devasia AJ, Nair SC, Janet NB, Abraham A, Mani T, Lakshmanan J, Balasubramanian P, George B, Mathews V. Fouzia NA, et al. Among authors: palani hk. Br J Haematol. 2021 Jan;192(2):292-299. doi: 10.1111/bjh.17221. Epub 2020 Nov 20. Br J Haematol. 2021. PMID: 33216980 Free PMC article.
Metabolic adaptation drives arsenic trioxide resistance in acute promyelocytic leukemia.
Balasundaram N, Ganesan S, Chendamarai E, Palani HK, Venkatraman A, Alex AA, David S, Kumar SP, Radhakrishnan NR, Yasar M, Krishna S, Korula A, Kulkarni U, Janet NB, Balasubramanian P, Mathews V. Balasundaram N, et al. Among authors: palani hk. Blood Adv. 2022 Jan 25;6(2):652-663. doi: 10.1182/bloodadvances.2021005300. Blood Adv. 2022. PMID: 34625794 Free PMC article.
Real world data with concurrent retinoic acid and arsenic trioxide for the treatment of acute promyelocytic leukemia.
Kulkarni UP, Selvarajan S, Lionel S, Prakash MA, Palani HK, Balasundaram N, Venkataraman A, Korula A, Devasia AJ, Fouzia NA, Janet NB, Nair SC, Abraham A, Mani T, Lakshmanan J, Arunachalam AK, Balasubramanian P, George B, Mathews V. Kulkarni UP, et al. Among authors: palani hk. Blood Cancer J. 2022 Jan 31;12(1):22. doi: 10.1038/s41408-022-00619-3. Blood Cancer J. 2022. PMID: 35102152 Free PMC article. No abstract available.
17 results